Susan Minton

4.3k citations

41 papers · 2.9k indexed · h-index 22

Molecular Biology top 5%
Oncology top 2%
Cancer Research top 5%
Pulmonary and Respiratory Medicine top 10%
Genetics top 5%

Co-authors: Pamela N. Münster Daniel M. Sullivan Roohi Ismail‐Khan Ji‐Hyun Lee M. Lacevic Robert A. Gatenby Yoonseok Kam Robert J. Gillies
Topics: HER2/EGFR in Cancer Research (6 papers)Tryptophan and brain disorders (6 papers)Cancer, Stress, Anesthesia, and Immune Response (5 papers)
Cited by: Biological Psychiatry Oncology Cancer Research
Journals: Nature Genetics Journal of Clinical Oncology PLoS ONE
Partner nations: United States Canada United Kingdom

In The Last Decade

Susan Minton

40 papers receiving 2.9k citations

Peers

Countries citing papers authored by Susan Minton

Since Specialization

Citations

This map shows the geographic impact of Susan Minton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Minton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Minton more than expected).

Fields of papers citing papers by Susan Minton

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Minton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Minton. The network helps show where Susan Minton may publish in the future.

Co-authorship network of co-authors of Susan Minton

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Minton. A scholar is included among the top collaborators of Susan Minton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Minton. Susan Minton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A phase I study of MK-5108, an oral aurora a kinase inhibitor, administered both as monotherapy and in combination with docetaxel, in patients with advanced or refractory solid tumors 2015 ·Investigational New Drugs ·Manik Amin,Susan Minton,Patricia LoRusso,Smitha Krishnamurthi,Cheryl A. Pickett,Jared Lunceford,Darcy A. Hille,David Mauro,Mark N. Stein,Andrea Wang‐Gillam,(unknown),A. Craig Lockhart	35
2	Phase 1 trial of the oral AKT inhibitor MK-2206 plus carboplatin/paclitaxel, docetaxel, or erlotinib in patients with advanced solid tumors 2014 ·Journal of Hematology & Oncology ·L. Rhoda Molife,Yan Li,Joanna Vitfell-Rasmussen,(unknown),Daniel M. Sullivan,Philippe A. Cassier,Eric X. Chen,Andrea Biondo,Ernestina Tetteh,Lillian L. Siu,Amita Patnaik,Kyriakos P. Papadopoulos,Johann S. de Bono,Anthony W. Tolcher,Susan Minton	148
3	Evolutionary Strategy for Systemic Therapy of Metastatic Breast Cancer: Balancing Response with Suppression of Resistance 2014 ·Women s Health ·Yoonseok Kam,Tuhin Das,Susan Minton,Robert A. Gatenby	15
4	Evolutionary Approaches to Prolong Progression-Free Survival in Breast Cancer 2012 ·Cancer Research ·Ariosto S. Silva,Yoonseok Kam,(unknown),Susan Minton,Robert J. Gillies,Robert A. Gatenby	111
5	An exploratory study to determine if BRCA1 and BRCA2 mutation carriers have higher risk of cardiac toxicity. 2012 ·Journal of Clinical Oncology ·Roohi Ismail‐Khan,(unknown),Weihong Sun,Hatem Soliman,Hyo S. Han,Susan Minton,Johnathan M. Lancaster,Tuya Pal	2
6	HER2-positive male breast cancer with thyroid cancer: an institutional report and review of literature. 2012 ·PubMed ·(unknown),Marilyn M. Bui,Susan Minton,Loretta Loftus,(unknown),Christine Laronga,Roohi Ismail‐Khan	3
7	History of Major Depressive Disorder Prospectively Predicts Worse Quality of Life in Women with Breast Cancer 2011 ·Annals of Behavioral Medicine ·Heather Jim,Brent J. Small,Susan Minton,Michael A. Andrykowski,Paul B. Jacobsen	29
8	Sunitinib Plus Paclitaxel Versus Bevacizumab Plus Paclitaxel for First-Line Treatment of Patients With Advanced Breast Cancer: A Phase III, Randomized, Open-Label Trial 2011 ·Clinical Breast Cancer ·Nicholas J. Robert,Mansoor N. Saleh,Devchand Paul,Daniele Generali,Laurent Gressot,Mehmet S Copur,Adam Brufsky,Susan Minton,Jeffrey K. Giguere,John W. Smith,Paul Richards,Diana Gernhardt,Xin Huang,Katherine Liau,Kenneth A. Kern,Jason J. Davis	94
9	Relationship of Exercise to Quality of Life in Cancer Patients Beginning Chemotherapy 2011 ·Journal of Pain and Symptom Management ·Leigh Anne Faul,Heather Jim,Susan Minton,Mayer Fishman,Tawee Tanvetyanon,Paul B. Jacobsen	20
10	Male Breast Cancer: Management and Follow-up Recommendations 2011 ·The Breast Journal ·John V. Kiluk,Marie Catherine Lee,(unknown),Tammi Meade,Susan Minton,Eleanor Harris,Jongphil Kim,Christine Laronga	50
11	A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer 2011 ·British Journal of Cancer ·Pamela N. Münster,Kenneth T. Thurn,Scott Thomas,Paromita Raha,M. Lacevic,Alexandra Miller,Michelle Melisko,Roohi Ismail‐Khan,Hope S. Rugo,Mark M. Moasser,Susan Minton	315
12	Necdin, a Negative Growth Regulator, Is a Novel STAT3 Target Gene Down-Regulated in Human Cancer 2011 ·PLoS ONE ·(unknown),Steven A. Eschrich,Gregory Bloom,Yihong Ma,Susan Minton,Richard Jove,W. Douglas Cress	17
13	Phase 2 study of gemcitabine and irinotecan in metastatic breast cancer with correlatives to determine topoisomerase I localization as a predictor of response 2008 ·Cancer ·Stacy L. Moulder,(unknown),Anthony Neuger,Jimin Choi,Ji‐Hyun Lee,Susan Minton,Pamela N. Münster,Jana Gump,(unknown),Richard M. Lush,Dan M. Sullivan	15
14	First Study of the Safety, Tolerability, and Pharmacokinetics of CP-724,714 in Patients with Advanced Malignant Solid HER2-Expressing Tumors 2007 ·Clinical Cancer Research ·Pamela N. Münster,Carolyn D. Britten,Monica Mita,Karen A. Gelmon,Susan Minton,Stacy L. Moulder,Dennis J. Slamon,Feng Guo,Stephen P. Letrent,Louis Denis,Anthony W. Tolcher	24
15	Is cytoplasmic localization of topoisomerase I (topo I) a mechanism of resistance for topo I inhibitors? Results from an NCCN sponsored phase II trial of gemcitabine and irinotecan in metastatic breast cancer. 2006 ·Cancer Research ·Stacy Moulder,Nikola Valkov,Jana Gump,Pamela N. Münster,Susan Minton,John Horton,M. Lacevic,(unknown),Dan M. Sullivan	1
16	Sentinel Node Biopsy Before Neoadjuvant Chemotherapy for Determining Axillary Status and Treatment Prognosis in Locally Advanced Breast Cancer 2006 ·Annals of Surgical Oncology ·Charles E. Cox,John M. Cox,Laura White,(unknown),John D. Clark,(unknown),Michael P. Meyers,Elisabeth Dupont,Ben Furman,Susan Minton	47
17	Activation of Stat3 in Primary Tumors from High-Risk Breast Cancer Patients Is Associated with Elevated Levels of Activated Src and Survivin Expression 2006 ·Clinical Cancer Research ·(unknown),Susan Minton,Charles Cox,Tammy Bowman,(unknown),Roy Garcia,(unknown),Marek Wloch,(unknown),(unknown),Alan Cantor,Ji‐Hyun Lee,Craig A. Beam,Daniel M. Sullivan,Richard Jove,Carlos Muro‐Cacho	205
18	A Pilot Trial of Paroxetine for the Treatment of Hot Flashes and Associated Symptoms in Women with Breast Cancer 2002 ·Journal of Pain and Symptom Management ·Michael A. Weitzner,(unknown),Paul B. Jacobsen,Susan Minton	87
19	CHEMOPREVENTION OF BREAST CANCER IN THE OLDER PATIENT 2000 ·Hematology/Oncology Clinics of North America ·Susan Minton	8
20	Severe Lhermitte-Duclos disease with unique germline mutation of PTEN 1999 ·American Journal of Medical Genetics ·Rebecca Sutphen,(unknown),Susan Minton,Monica Peacocke,Hui C. Tsou,Allen W. Root	34

About Susan Minton

Susan Minton is a scholar working on Biological Psychiatry, Oncology and Cancer Research, having authored 41 papers that have together received 2.9k indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (6 papers), Tryptophan and brain disorders (6 papers) and Cancer, Stress, Anesthesia, and Immune Response (5 papers). The work is most often cited by research in Biological Psychiatry (179 citations), Oncology (1.4k citations) and Cancer Research (563 citations). Susan Minton has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Pamela N. Münster, Daniel M. Sullivan, Roohi Ismail‐Khan, Ji‐Hyun Lee, M. Lacevic, Robert A. Gatenby, Yoonseok Kam, Robert J. Gillies, Richard Jove and Craig A. Beam. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact